Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 150 mg/ml - injection, suspension - excipient ingredients: propyl hydroxybenzoate; methyl hydroxybenzoate; water for injections; sodium chloride; macrogol 3350; polysorbate 80 - carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contra- indicated or has been unsuccessful. contraception (ovulation suppression): for long-term prevention of pregnancy in women when administered at 3-month intervals. since loss of bone mineral density (bmd) may occur in pre-menopausal women who use depo-provera long-term (greater than 2 years), women should be assessed, before starting treatment for contraception or endometriosis, regarding the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achieve their predicted peak bone mineral density (see warnings). the 50 mg/1ml vial is not approved for the indication of contraception (ovulation suppression). the injection, depo-provera 1

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 150 mg/ml - injection, suspension - excipient ingredients: propyl hydroxybenzoate; methyl hydroxybenzoate; water for injections; sodium chloride; macrogol 3350; polysorbate 80 - carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contra- indicated or has been unsuccessful. contraception (ovulation suppression): for long-term prevention of pregnancy in women when administered at 3-month intervals. since loss of bone mineral density (bmd) may occur in pre-menopausal women who use depo-provera long-term (greater than 2 years), women should be assessed, before starting treatment for contraception or endometriosis, regarding the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achieve their predicted peak bone mineral density (see warnings). the 50 mg/1ml vial is not approved for the indication of contraception (ovulation suppression). the injection, depo-provera 150 mg/1ml, should be used for contraception.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - medroxyprogesterone acetate 150 mg/ml - injection (depot) - 150 mg/ml - active: medroxyprogesterone acetate 150 mg/ml excipient: hydrochloric acid macrogol 3350 methyl hydroxybenzoate polysorbate 80 propyl hydroxybenzoate sodium chloride sodium hydroxide - adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial or renal carcinoma

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - suspension for injection - medroxyprogesterone acetate 150 mg/ml - medroxyprogesterone - medroxyprogesterone - for contraception where medically indicated and oral administration is inapplicable.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pfizer laboratories (pty) ltd - injection - see ingredients - each 1 ml contains medroxyprogesterone acetate 150 mg

Canada - English - Health Canada

sterimax inc - levetiracetam - solution - 100mg - levetiracetam 100mg

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - depo-provera ci is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of depo-provera ci is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings and precautions (5.10)] . depo-provera ci

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - medroxyprogesterone acetate - injection - 50 mg/ml - medroxyprogesterone acetate 50 mg/ml

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone 400 mg in 1 ml - adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. - known or suspected pregnancy or as a diagnostic test for pregnancy - undiagnosed vaginal bleeding - known or suspected malignancy of breast - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease - liver dysfunction or disease - known sensitivity to depo-provera (medroxyprogesterone acetate or any of its other ingredients).

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease - known sensitivity to depo-provera (medroxyprogesterone acetate or any of its other ingredients).